Hemostatic system activation in breast cancer: Searching for new biomarkers for cancer risk prediction and outcomes. Issue 213 (May 2022)

• Record Type: Journal Article
• Authors: Marchetti, Marina; Russo, Laura; Giaccherini, Cinzia; Gamba, Sara; Falanga, Anna
• Is Part Of: Thrombosis research. Issue 213(2022)Supplement 1
• Page Start: S46
• Page End: S50
• Publication Date: 2022-05
• Subjects: Hemostatic biomarkers -- Breast cancer risk -- Cancer diagnosis -- Tumor cells -- Procoagulants -- Hemostasis; Thrombosis -- Periodicals; 616.135
• DOI: 10.1016/j.thromres.2022.01.019
• Languages: English
• ISSNs: 0049-3848

Abstract

Abstract: In malignant diseases, the development of a systemic hypercoagulable state is the consequence of the procoagulant activity of cancer cells on the hemostatic system and based on this close relationship, alterations in the levels of hemostatic biomarkers and/or biomarkers of blood clotting activation are under investigation as a potential tool in predicting for different cancer outcomes. Today, breast cancer remains the most common tumor and the second cause of mortality for cancer in women. There is still a need for novel biomarkers for making a diagnosis at a very early stage of disease and for the classification of individuals at different risks of disease recurrence or progression. In this review, we will discuss the pathogenesis of the thrombophilic state in breast cancer patients and its interconnection with the mechanisms of malignant progression, and report on the latest results from the HYPERCAN study in the context of hemostatic biomarker development in the breast cancer setting. Highlights: The hypercoagulable state induced by cancer favors different processes associated with tumor growth and dissemination. Breast cancer patients display different grades of blood clotting alterations. A role of hemostatic biomarkers for breast cancer risk prediction and outcomes is suggested.